All-Inclusive: Personalized Drug Metabolism by Microbiota in Gut Organoids

The metabolism of drugs takes place for the most part in the liver. Next to the liver, however, microbiota in the gut also play an active role in the metabolism of drugs, either in generating active compounds or deactivating the drug. In vivo, the gastrointestinal tract is populated by a complex and highly individual microbiota. Gut organoids are powerful ex vivo tools for studying drug metabolism. Organoids also allow for studying the role of microbiota in drug metabolism. The technical challenges in co-culturing eukaryotic organoids with prokaryotic bacteria are considerable and have only partly been overcome. Next steps will include mimicking the complex composition of the gut microbiome and distinguishing between host and microbial metabolites. This manuscript provides a state-of-the-art overview of current concepts and of the most promising avenues for future research and applications in drug development.

Authors

Publication Details

Journal
Pharmaceuticals
Published
2026-11-19
DOI
https://doi.org/10.3390/ph19111844
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

All-Inclusive: Personalized Drug Metabolism by Microbiota in Gut Organoids

Ger T. Rijkers, K. Herega
2 links
Pharmaceuticals
Gut microbiota and health
article

All-Inclusive: Personalized Drug Metabolism by Microbiota in Gut Organoids

Ger T. Rijkers, K. Herega
article en

Abstract

The metabolism of drugs takes place for the most part in the liver. Next to the liver, however, microbiota in the gut also play an active role in the metabolism of drugs, either in generating active compounds or deactivating the drug. In vivo, the gastrointestinal tract is populated by a complex and highly individual microbiota. Gut organoids are powerful ex vivo tools for studying drug metabolism. Organoids also allow for studying the role of microbiota in drug metabolism. The technical challenges in co-culturing eukaryotic organoids with prokaryotic bacteria are considerable and have only partly been overcome. Next steps will include mimicking the complex composition of the gut microbiome and distinguishing between host and microbial metabolites. This manuscript provides a state-of-the-art overview of current concepts and of the most promising avenues for future research and applications in drug development.

PharmaceuticalsVol. 19(11)
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon